Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workforce reduced by 35%. Financially secure with $175M cash. Strategic focus on key developments in 2024.
Related Keywords
William Blair , Bristol Myers Squibb Company , , Ikena Oncology , Selective Hippo Pathway , Bristol Myers Squibb ,
comparemela.com © 2020. All Rights Reserved.